LifeMD, Inc. · NASDAQ:LFMD

LifeMD — Q1 2023 Earnings Presentation

9 slides from LifeMD's earnings presentation, May 2023

  1. Slide 1: Supplemental Q1 2023 Presentation

    Supplemental Q1 2023 Presentation May 2023

  2. Slide 2: Important Cautions Regarding Forward-Looking Statements

    Important Cautions Regarding Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private

  3. Slide 3: Highlights: Q1 2023

    Highlights: Q1 2023 Revenue: LifeMD Virtual Primary Care Brand: Total revenue for Q1 2023 totaled $33.1M, up 14% from the year ago Virtual primary care (VPC) platform ends Q1 with 11,000 patients period. Up 18% from Q4’22. Telehealth revenue up 23% from Q4 ’22. and $565K in revenue +106% sequentiall

  4. Slide 4: Early Mover Advantage, Supported By A Patient-Centric Approach, Has Enabled Incredible Growth

    $140-$150M Early Mover Advantage, Supported By A Patient-Centric Approach, Has Enabled Incredible Growth $119M $36M $140M - $150M $93M 2023E Revenue Forecast $25M 18% - 26% $83M YoY Estimated Revenue $37M Growth in ‘23 $68M $7M $13M $30M 715K+ $11M $2M Patients & Customers To-Date 2019A 2020A 2021A

  5. Slide 5: Rapidly Accelerating Gross Margins And Increasing Leverage On Marketing Spend

    Rapidly Accelerating Gross Margins And Increasing Leverage On Marketing Spend Driving Continued Growth In Profitability Consolidated Gross Margin % Marketing Expenses as % of Sales 35 125% 90% 88% 32 100% Net Revenue ($ Millions) 86% 77% 75% 84% 72% 29 75% 62% 82% 55% 50% 80% 26 50% 78% 23 25% 76% 7

  6. Slide 6: Full Year 2023 Guidance Reflecting Substantial Profitability Growth

    Full Year 2023 Guidance Reflecting Substantial Profitability Growth FY 2023 GUIDANCE FY 2022 ACTUAL DELTA % Consolidated Net Revenue $140-$150 million $119 million +18-26% Gross Margin % 87% 84% +300 bps Consolidated Adj. EBITDA $12-$18 million $(15) million +180-220% Free Cash Flow Break-Even Reach

  7. Slide 7: Strong Liquidity to Meet our Capital and Growth Needs

    Strong Liquidity to Meet our Capital and Growth Needs FY 2023 CASH FLOW GUIDANCE End of Year 2022 Actual Cash Balance $4 million Plus Avenue Capital FY23 Debt Proceeds, net +$18 million Operating Cash Flow (incl. Interest Expense) +$4-$8 million Less Capex $(6)-$(8) million Less Preferred Dividends

  8. Slide 8: Investor Highlights

    Investor Highlights Significant presence within massive and growing addressable markets Proprietary technology platform differentiated by leading 50-state, affiliated physician network High margin products/services generating 85%+ consolidated gross margins EBITDA break-even with significant 2023 EB

  9. Slide 9: Company Contact

    Company Contact Marc Benathen marc@lifemd.com

LifeMD — Q1 2023 Earnings Presentation on 6ix